We’re excited to announce that we have entered into a definitive agreement to acquire Amicus Therapeutics, adding new therapies for Fabry disease and Pompe disease.

This transaction has the potential to expand BioMarin’s position as a leader in rare diseases, enabling these innovative medicines to reach more individuals around the world and strengthening our financial outlook.

Read more in our press release: http://ms.spr.ly/6042toNsG

$BMRN